Coherus Oncology (CHRS) Debt Ratio (2014 - 2026)

Coherus Oncology (CHRS) posted Debt Ratio of 0.14 for Q1 2026, down 2.63% sequentially from 0.14 in Q4 2025, and up 40.87% YoY from 0.1 in Q1 2025.

Coherus Oncology (CHRS) Debt Ratio (2014 - 2026) Analysis & Trends

Coherus Oncology has reported Debt Ratio for 13 years, with the latest figure at 0.14 in Q1 2026.

Quarterly Debt Ratio rose 40.87% year-over-year to 0.14 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.14 (up 40.87% YoY) and the FY2025 annual result came in at 0.14, up 75.29% from the prior year.
Debt Ratio slipped to 0.14 in Q1 2026 per CHRS's latest filing, from 0.14 in the prior quarter.
Over five years, Debt Ratio peaked at 0.61 in Q1 2023 and troughed at 0.05 in Q2 2024.
A 5-year average of 0.26 and a median of 0.14 in 2025 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2022 and 2024: Debt Ratio soared 359.28% in 2022, then slumped 89.66% in 2024.
Over 5 years, Debt Ratio stood at 0.51 in 2022, then retreated by 22.29% to 0.4 in 2023, then sank by 79.38% to 0.08 in 2024, then jumped by 75.29% to 0.14 in 2025, then decreased by 2.63% to 0.14 in 2026.
According to Business Quant data, Debt Ratio over the past three periods registered 0.14, 0.14, and 0.07 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	138.04 Bn	130.18 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.98 Bn	77.98 Bn	3.93 Bn	0.05
3	Argenx Se	64.37 Bn	59.19 Bn	1.37 Bn	-
4	Moderna	57.67 Bn	52.53 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.94 Bn	36.84 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
7	BioNTech SE	27.75 Bn	9.35 Bn	668.28 Mn	0.03
8	Insmed	27.24 Bn	26.08 Bn	358.27 Mn	0.26
9	Royalty Pharma	27.03 Bn	26.20 Bn	-	0.47
10	Coherus Oncology	206.06 Mn	100.76 Mn	10.07 Mn	0.19

Download Data